(Las Vegas, Nevada, United States)  As per DelveInsight’s assessment, globally, Relapsing Refractory Multiple Myeloma pipeline constitutes 55+ key companies continuously working towards developing 60+ Relapsing Refractory Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. 

 

“Relapsing Refractory Multiple Myeloma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Relapsing Refractory Multiple Myeloma Market.

 

The Relapsing Refractory Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Relapsing Refractory Multiple Myeloma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Relapsing Refractory Multiple Myeloma treatment therapies with a considerable amount of success over the years. 
• Relapsing Refractory Multiple Myeloma companies working in the treatment market are Artiva Biotherapeutics, Ionis Pharmaceuticals, MiNK Therapeutics, AbbVie, Ichnos Sciences, Sorrento Therapeutics, Alfa Takeda, Array BioPharma, Novartis, Gilead Sciences, Arcellx, Inc., Pfizer, Bristol-Myers Squibb, Cellectar Biosciences, Inc., ORIC Pharmaceuticals, and others, are developing therapies for the Relapsing Refractory Multiple Myeloma treatment 
• Emerging Relapsing Refractory Multiple Myeloma therapies in the different phases of clinical trials are- AB-101, ION251, agenT-797, ABBV-383, ISB 1442, STI-6129, Modakafusp, Encorafenib, PHE885, Magrolimab, CART-ddBCMA, Elranatamab, Mezigdomide, Iopofosine, ORIC-533, and others are expected to have a significant impact on the Relapsing Refractory Multiple Myeloma market in the coming years.   
• In December 2022, Kite, a Gilead Company and Arcellx, Inc. announced a global strategic collaboration to co-developand co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients withrelapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the needremains for effective, safe, and broadly accessible therapies.
• In September 2022, Bristol-Myers Squibb initiated a Phase III, two-stage, randomized, multicenter, openlabel study comparing CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib anddexamethasone (PVd) in subjects with Relapsed or Refractory Multiple Myeloma (RRMM).
• In August 2022, Arcellx, Inc. a Phase II open-label study of CART-ddBCMA in patients with relapsed orrefractory multiple myeloma (MM). The study will have the following sequential phases: screening, enrollment, pretreatment with lymphodepleting chemotherapy, treatment with CART-ddBCMA, and follow-up. If necessary, bridgingtherapy is allowed to control growth of MM disease while CART-ddBCMA is being manufactured.
• In March 2022, Arcellx, announced that the US Food and Drug Administration (FDA) has granted Orphan DrugDesignation to CART-ddBCMA, its engineered T cell therapy utilizing a novel binding domain, for the treatment ofpatients with multiple myeloma. In February 2020, CART-ddBCMA had been granted FDA fast track designation forpatients with relapsed or refractory multiple myeloma.

 

Relapsing Refractory Multiple Myeloma Overview

A hematologic condition known as multiple myeloma (MM) is characterised by an overgrowth of malignant, monoclonal plasma cells in the bone marrow (BM) and/or extramedullary locations. When a patient receives treatment for multiple myeloma, but the malignancy recurs or does not react to the medication, this condition is known as relapsed refractory multiple myeloma (RRMM).

 

Get a Free Sample PDF Report to know more about Relapsing Refractory Multiple Myeloma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight

 

Emerging Relapsing Refractory Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:

• AB-101: Artiva Biotherapeutics
• ION251: Ionis Pharmaceuticals
• agenT-797: MiNK Therapeutics
• ABBV-383: AbbVie
• ISB 1442: Ichnos Sciences
• STI-6129: Sorrento Therapeutics
• Modakafusp: Alfa Takeda
• Encorafenib: Array BioPharma
• PHE885: Novartis
• Magrolimab: Gilead Sciences
• CART-ddBCMA: Arcellx, Inc.
• Elranatamab: Pfizer
• Mezigdomide: Bristol-Myers Squibb
• Iopofosine: Cellectar Biosciences, Inc.
• ORIC-533: ORIC Pharmaceuticals

 

Relapsing Refractory Multiple Myeloma Route of Administration

Relapsing Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Relapsing Refractory Multiple Myeloma Molecule Type

Relapsing Refractory Multiple Myeloma Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

 

Relapsing Refractory Multiple Myeloma Pipeline Therapeutics Assessment

• Relapsing Refractory Multiple Myeloma Assessment by Product Type
• Relapsing Refractory Multiple Myeloma By Stage and Product Type
• Relapsing Refractory Multiple Myeloma Assessment by Route of Administration
• Relapsing Refractory Multiple Myeloma By Stage and Route of Administration
• Relapsing Refractory Multiple Myeloma Assessment by Molecule Type
• Relapsing Refractory Multiple Myeloma by Stage and Molecule Type

 

DelveInsight’s Relapsing Refractory Multiple Myeloma Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Relapsing Refractory Multiple Myeloma product details are provided in the report. Download the Relapsing Refractory Multiple Myeloma pipeline report to learn more about the emerging Relapsing Refractory Multiple Myeloma therapies

 

Some of the key companies in the Relapsing Refractory Multiple Myeloma Therapeutics Market include:

Key companies developing therapies for Relapsing Refractory Multiple Myeloma are – Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Theraputics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc., Seagen Inc., Trillium Therapeutics Inc., and others.

 

Relapsing Refractory Multiple Myeloma Pipeline Analysis:

The Relapsing Refractory Multiple Myeloma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing Refractory Multiple Myeloma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing Refractory Multiple Myeloma Treatment.
• Relapsing Refractory Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Relapsing Refractory Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing Refractory Multiple Myeloma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Relapsing Refractory Multiple Myeloma drugs and therapies

 

Relapsing Refractory Multiple Myeloma Pipeline Market Drivers

• Players focusing on innovation of newer products and collaboration strategies, increase in the prevalence of relapsed and refractory multiple myeloma, funding for the R&D activities from public and private sectors are some of the important factors that are fueling the Relapsing Refractory Multiple MyelomaMarket.

 

Relapsing Refractory Multiple Myeloma Pipeline Market Barriers

• However, stringent regulations for product approval, adverse effects associated with the drugs and other factors are creating obstacles in the Relapsing Refractory Multiple Myeloma Market growth.

 

Scope of Relapsing Refractory Multiple Myeloma Pipeline Drug Insight    

• Coverage: Global
• Key Relapsing Refractory Multiple Myeloma Companies: Artiva Biotherapeutics, Ionis Pharmaceuticals, MiNK Therapeutics, AbbVie, Ichnos Sciences, Sorrento Therapeutics, Alfa Takeda, Array BioPharma, Novartis, Gilead Sciences, Arcellx, Inc., Pfizer, Bristol-Myers Squibb, Cellectar Biosciences, Inc., ORIC Pharmaceuticals, and others
• Key Relapsing Refractory Multiple Myeloma Therapies: AB-101, ION251, agenT-797, ABBV-383, ISB 1442, STI-6129, Modakafusp, Encorafenib, PHE885, Magrolimab, CART-ddBCMA, Elranatamab, Mezigdomide, Iopofosine, ORIC-533, and others
• Relapsing Refractory Multiple Myeloma Therapeutic Assessment: Relapsing Refractory Multiple Myeloma current marketed and Relapsing Refractory Multiple Myeloma emerging therapies
• Relapsing Refractory Multiple Myeloma Market Dynamics: Relapsing Refractory Multiple Myeloma market drivers and Relapsing Refractory Multiple Myeloma market barriers 

 

Request for Sample PDF Report for Relapsing Refractory Multiple Myeloma Pipeline Assessment and clinical trials

 

Table of Contents 

1. Relapsing Refractory Multiple Myeloma Report Introduction

2. Relapsing Refractory Multiple Myeloma Executive Summary

3. Relapsing Refractory Multiple Myeloma Overview

4. Relapsing Refractory Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment

5. Relapsing Refractory Multiple Myeloma Pipeline Therapeutics

6. Relapsing Refractory Multiple Myeloma Late Stage Products (Phase II/III)

7. Relapsing Refractory Multiple Myeloma Mid Stage Products (Phase II)

8. Relapsing Refractory Multiple Myeloma Early Stage Products (Phase I)

9. Relapsing Refractory Multiple Myeloma Preclinical Stage Products

10. Relapsing Refractory Multiple Myeloma Therapeutics Assessment

11. Relapsing Refractory Multiple Myeloma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Relapsing Refractory Multiple Myeloma Key Companies

14. Relapsing Refractory Multiple Myeloma Key Products

15. Relapsing Refractory Multiple Myeloma Unmet Needs

16 . Relapsing Refractory Multiple Myeloma Market Drivers and Barriers

17. Relapsing Refractory Multiple Myeloma Future Perspectives and Conclusion

18. Relapsing Refractory Multiple Myeloma Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/arthroscopy-devices-market